Baricitinib (BARIDOZ) will be launched in India for COVID-19 treatment
MSN Labs has entered into a royalty-free, non-exclusive, voluntary license agreement with Eli Lilly and Company of USA for manufacturing and marketing of baricitinib for COVID-19 in India.
The drug baricitinib has been granted a restricted emergency use approval in India by the Central Drugs Standard Control Organization for emergency use in combination with remdesivir for the treatment of suspected or laboratory-confirmed COVID-19 in hospitalised adults requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).
Dr MSN Reddy, CMD – MSN Group, commented “This collaboration with Eli Lilly and company is a landmark milestone in India’s fight against COVID-19 and will thus help in increasing the availability and affordability of baricitinib”.